SPEVIGO: payments to doctors
Payments that named SPEVIGO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3.3M
- Providers
- 9,788
- Transactions
- 25,439
- Average per transaction
- $128
The per-transaction average — $128 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 9,788 providers the average total is $333, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $3,021,755 | 92.6% |
| Boehringer Ingelheim International GmbH | $165,414 | 5.1% |
| LEO Pharma Inc. | $70,549 | 2.2% |
| Boehringer Ingelheim RCV GmbH & Co KG | $5,850 | 0.2% |